ISIS Trial Is Now Enrolling Patients
This 1 year long trial will study the effect of inhaled hypertonic saline in children aged 4 months to 5 years. For more information click here. PCT124 Trial Is Now Enrolling
The PTC124 trial at Johns Hopkins is now enrolling patients aged 6 and up with CF. PTC124 is an oral medication designed to help patients with nonsense CFTR mutations. This would be anyone with the letter ‘X’ in their mutation name. A description of the study can be obtained by clicking here. For more information contact Karen Callahan at 443-287-8983 or by e-mail. Hear Dr. Eitan Kerem Speak About PTC124
Dr. Kerem's presentation to the Johns Hopkins CF Center is online. Dr. Kerem is a world known leader in CF research who has been at the forefront of the development of PTC124. Click here to view the presentation. The Family Day Talks Are Online
The Johns Hopkins Annual CF Family Education held on November 21st was a great success. You can view all the lectures by clicking here. All four talks can be viewed including: Introductory remarks by Dr. Mogayzel; Exercise and CF by Dr. Paranjape; An Adult Patient Perspective by Chris Dopher and the keynote address by Dr. Robert Beall, President and CEO of the CF Foundation on the Future of CF Research. CF Foundation Wins Quality Improvement Award
The CF Foundation received a 2009 Health Quality Award from the National Committee for Quality Assurance. This prestigious award was given for the quality improvement work sponsored by the CF Foundation at care centers such as Johns Hopkins. Click here to view a video about the award. | |
|
